IL1B and melanoma: CCK-8 assay illustrated loss of IL1B significantly inhibited the viability of vemurafenib-resistant A375R melanoma cells, while overexpression of IL1B strongly increased the viability of vemurafenib-resistant A375R cells (Fig. 4D).